Memory Deficits Due to Familial British Dementia BRI2 Mutation Are Caused by Loss of BRI2 Function Rather than Amyloidosis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Familial dementias, which include Alzheimer disease (AD), familial British dementia (FBD), and familial Danish dementia (FDD), are caused by dominantly inherited autosomal mutations and are characterized by the production of amyloidogenic peptides, neurofibrillary tangles (NFTs) and neurodegeneration (St George-Hyslop and Petit, 2005; Garringer et al., 2009). The prevailing pathogenic theory, the “amyloid cascade hypothesis” (Hardy and Selkoe, 2002), posits that the accumulation of amyloidogenic peptides triggers tauopathy, neurodegeneration, and cognitive and behavioral changes. However, this hypothesis is yet to be validated, and causes of dementia may be multifaceted and involve other mechanisms, such as loss of function due to pathogenic mutations. Mouse models of human dementia invariably use transgenic expression systems (LaFerla and Oddo, 2005; McGowan et al., 2006; Vidal et al., 2009; Coomaraswamy et al., 2010) that do not reflect the genotypes of human disease and cannot replicate loss of function. Therefore, we generated a knock-in (KI) mouse model of FBD (FBD KI) genetically congruous with the human disease. FBD is caused by a missense mutation at the stop codon of the BRI2 gene (Vidal et al., 1999) and, like FBD patients, FBD KI mice carry this mutation in one of the two murine Bri2 alleles. We report that the British mutation drastically reduces expression of mature BRI2 in both KI mice and human FBD brains. This deficit is associated with severe hippocampal memory deficits in FBD KI mice. Remarkably, these animals showed no cerebral amyloidosis and tauopathy.Bri2+/−mice present memory deficits similar to those in FBD KI animals. Collectively, these results indicate that the British BRI2 mutation underlies abnormal memory due to loss of BRI2 function and independently of histopathological alterations typically evident in advanced neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bourtchuladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schutz, G., & Silva, A. J. (1994) · Cell · doi:10.1016/0092-8674(94)90400-6 · Cited by 1,800 · cited 1×
“FBDKI and WT littermates 9 months of age were subjected to a standard fear-conditioning paradigm (Bourtchuladze et al., 1994).”
MethodSaura, C. A., Choi, S.-Y., Beglopoulos, V., Malkani, S., Zhang, D., Rao, B. S. S., Chattarji, S., Kelleher, R. J., Kandel, E. R., Duff, K., et al. (2004) · Neuron · doi:10.1016/s0896-6273(04)00182-5 · Cited by 757 · cited 2×
“Mutations in PSEN1/PSEN2, which cause familial AD, reduce PSEN1/PSEN2 function (De Strooper, 2007) and deletion of PSEN1/PSEN2 in mouse brains causes neurodegeneration, synaptic dysfunction and memory loss (Saura et al., 2004; Zhang et al., 2009).”
BackgroundA stop-codon mutation in the BRI gene associated with familial British dementia
Vidal, R., Frangione, B., Rostagno, A., Mead, S., Révész, T., Plant, G., & Ghiso, J. (1999) · Nature · doi:10.1038/21637 · Cited by 466 · cited 4×
“BRI2 is a type II transmembrane protein that belongs to a multigene family comprising BRI1, BRI2 and BRI3 (also referred to as ITM2A, ITM2B and ITM2C, or E25A, E25B and E25C, respectively) (Deleersnijder et al., 1996; Pittois et al., 1999; Vidal et al., 1999, 2000, 2001) in both mice and human.”
BackgroundInfluentialSelf-citationVidal, R., Révész, T., Rostagno, A., Kim, E., Holton, J. L., Bek, T., Bojsen-Møller, M., Braendgaard, H., Plant, G., Ghiso, J., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080076097 · Cited by 300 · cited 15×
“Differently from the FDDKI, we produced a 332 bp fragment containing the ABri mutation (t798a substitution, leading to a Stop3R transition at codon 267 and to the introduction of an XbaI site at nucleotide 799), plus a humanizing substitution a3g (acc3gcc Threonine3Alanine) at the 12th codon of exon 6, by serial PCRs,…”
BackgroundInfluentialSelf-citationA decade of modeling Alzheimer's disease in transgenic mice
MCGOWAN, E., ERIKSEN, J., & HUTTON, M. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.03.007 · Cited by 287 · cited 4×
“…model for FBD. Mouse models for human dementias are conventionally based on a transgenic approach in which human mutant proteins that cause familial forms of dementia are overexpressed under the control of brainspecific promoters (Price et al., 2000; LaFerla and Oddo, 2005; McGowan et al., 2006).”
BackgroundInfluentialMatsuda, S., Giliberto, L., Matsuda, Y., Davies, P., McGowan, E., Pickford, F., Ghiso, J., Frangione, B., & D'Adamio, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500217200 · Cited by 141
Self-citationBRI2 (ITM2b) Inhibits A Deposition In Vivo
Kim, J., Miller, V. M., Levites, Y., West, K. J., Zwizinski, C. W., Moore, B. D., Troendle, F. J., Bann, M., Verbeeck, C., Price, R. W., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0891-08.2008 · Cited by 120
BRI2 Interacts with Amyloid Precursor Protein (APP) and Regulates Amyloid β (Aβ) Production
Fotinopoulou, A., Tsachaki, M., Vlavaki, M., Poulopoulos, A., Rostagno, A., Frangione, B., Ghiso, J., & Efthimiopoulos, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500231200 · Cited by 114
Vidal, R., Barbeito, A. G., Miravalle, L., & Ghetti, B. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00164.x · Cited by 60 · cited 7×
“, 2009) by using primary antibodies directed against the following antigens: glial fibrillary acidic protein (GFAP) (Dako), ubiquitin (Dako), amyloid protein (A ) clone 4G8 (Signet Laboratories); microtubule-associated protein tau phosphorylated at Ser202/Thr205 (AT8, Pierce Biotechnology, Rockford, IL), keratan sulfa…”
BackgroundMethodInfluentialSelf-citation
Cited by
Tamayev, R., Matsuda, S., Arancio, O., & D'Adamio, L. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100195 · Cited by 142
Self-citationTamayev, R., & D’Adamio, L. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-19 · Cited by 81
“© 2012 Tamayev and D'Adamio; licensee BioM Creative Commons Attribution License (http:// reproduction in any medium, provided the or caused by APP/PSEN mutations are classified as FAD and those caused by mutations in BRI2/ITM2b as Familial Danish or British dementias (FDD or FBD), recent evidence suggest that FBD and…”
BackgroundSelf-citationRen, S., Yao, W., Tambini, M. D., Yin, T., Norris, K. A., & D'Adamio, L. (2020) · eLife · doi:10.7554/elife.57513 · Cited by 68
Self-citationRen, S., Breuillaud, L., Yao, W., Yin, T., Norris, K. A., Zehntner, S. P., & D’Adamio, L. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.016395 · Cited by 47
Self-citationTambini, M. D., Yao, W., & D'Adamio, L. (2019) · Aging Cell · doi:10.1111/acel.13033 · Cited by 40
Self-citation
Metadata
- Authors
- Tamayev, R., Giliberto, L., Li, W., d'Abramo, C., Arancio, O., Vidal, R., & D'Adamio, L.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-11-03
- Volume
- 30
- Issue
- 44
- Pages
- 14915-14924
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2047567148
- Cited by
- 55
- References
- 9
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Memory Deficits Due to Familial British Dementia BRI2 Mutation Are Caused by Loss of BRI2 Function Rather than Amyloidosis. https://app.cochat.ai/papers/10.1523/jneurosci.3917-10.2010
- The paper
- Tamayev, R., Giliberto, L., Li, W., d'Abramo, C., Arancio, O., Vidal, R., & D'Adamio, L. (2010). Memory Deficits Due to Familial British Dementia BRI2 Mutation Are Caused by Loss of BRI2 Function Rather than Amyloidosis. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.3917-10.2010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.